Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why would Elite be bought by Purdue? Makes zero sense. Generic oxy is now coming off patent. There will be ton of other manufacturers…assuming Elite gets approved.
Scottrade used to charge % OTC trade value before TD acquired them. Trade fees were $50-100 back then.
Not what analysts do. They are assigned to cover it by their firm. They are blind to it being on the OTC.
I wouldn’t be surprised if he used a date as it falls exactly on the day after 10Q is due for filing. Nasrat wouldn’t be able to do this if Elite was a larger company as you have to plan around competitor earnings calls to avoid sell side analysts missing your call for their coverage write up. Since no analysts even know who we are today it’s not an issue.
And that would be mid-Nov. :)
Yes, Q2’s 10Q filing is due to SEC on 14th, 45 days after close, followed by next day’s cc on 15th.
Mid-Nov. Due 45 days after quarter close.
I’m sure they thought no one would notice.
And gen Vyvanse filing
You must have misinterpreted it. Your comment referred to money made hasn’t made people happy. Much more money will be made on Elite, which must mean it will lead to more unhappiness. 😃
Bids are drying up. Lack of news will likely create some retraction until news does materialize. Regardless, it’s just a matter of time at this point.
Can’t wait to see the unhappiness levels over the next year then.
You do realize Weezuhl knew the formulation had issues before it was submitted. The results were weak at best, which is what triggered the reformulation. Was a waste of time and resources when we had little to not develop the quality product to begin with and rush to submission. Applesauce doesn’t cut it.
Ha! I should have enough tenure to deposit 3 dicks.
My response was in jest. :)
Just remember, most of us have made dick so far. Not sure the bank will allow me to use it as a deposit.
Let’s get some approvals and company really start moving before an acquisition is even on the table. If we are first to file with Oxy, there is a significantly different premium that Elite would entertain.
Next FDA approval for dopamine agonist won’t do the job. That’s coming up soon. Too tiny of a product.
You lost me. What is this referencing?
I think what we’ve found over past couple of years is that the power of social media can create bee swarm effect for retail holders that can much more powerful than Wall Street ever anticipated. GameStop/Bitcoin/AMC are just a few simple examples of this. Large investment funds can’t buy, but small retail holders get in to the rush of excitement (many might be investing for first time) and drive waves of buying/selling on sheer emotions.
Bids starting to lighten up…
No need to uplist at all to be acquired. Uplisting has pros/cons. It opens door to larger investors, funds & indexes, which can help stabilize the share price. However, some of those investment funds are short term holders, which means regular flipping or even hold short. This is when IR is absolutely critical to target the right ownership through sell side analysts, road shows and investor conferences. You want to large target long-term holders.
Would be nice, but think it’s stuck as Elite can’t move forward with it since it has split ownership.
Please don’t be jealous of my corp finance experience. I think the last think I googled was Methotrexeate as it was in the news a few years back, which jogged my memory. I try to keep up on pharma news beyond Elite so I can cast a wider net as a consultant.
I could care less about your Middle East travels. Probably just looking for a new special goat breed. :)
I don’t think he has ever stated a share price goal for a buyout. He has stated he is willing to sell the company (since that is Nasrat’s only realistic way to liquidate ownership).
Large investment firms and funds can’t you can this, but small firms may dabble in ownership. Will be interesting to see if any new ownership filings take place for the quarter.
That’s what I thought. You misinterpreted some basic finance concept. Not a huge surprise for a government worker.
I have worked for so many companies that wouldn’t touch hiring a gov’t worker due to consistent ineptitude. I feel sorry for you dude. Really do.
Your post is so ridiculous. I post on here and finance yahoo under same name. No hidden agenda.
Please show me post # where any insight/response I provided was incorrect. I am more than happy to take ownership of any errors. Would love to see it. I’m guessing it was misread/misinterpreted.
Lol that’s what I thought. You simply stated to ignore R&D. In all acquisitions of which I have been a part, R&D has Never been ignored. Not once.
If there’s a benefit, it’s a synergy, but not excluded when taking into consideration from an acquisition or forward multiple standpoint.
Thanks for admitting you have zero experience in this space. Sit back down and pretend like you do from your computer.
Voice from another country. You must be in ‘Merica country! Lol
Quick question - how many pharma acquisitions have you been close to? Truly.
Last one I was part of was $2.2B acquisition of specialty pharma company from finance integration standpoint. How about you? Just curious.
Agreed, with mid-November Q2 fiscal results release and hopefully generic OxyContin news around time of antimetabolite approval. Will be good next 6 months. I’m eager to hear how R&D pipeline is getting replenished, upcoming filings (excl gen Vyvanse). I expect generic Concerta to be on deck for bioequivalency w/ filing 1H 2024. After this is filed, we don’t have ton of insight into next big opportunities.
If we do in fact get first to file and get past legal hurdles, this stock will absolutely fly.
We all know of the legal and operational issues. You can’t assume we are first in line. Would be great, but no one has that insight at this point and may not for several more months.
Lol amateur
I think today was new money having eyes on Elite where it should be and where it’s going. I expect plenty of volatility, but good days ahead.
Also, don’t expect to be first to file for generic oxy. Would be absolutely awesome. We have no idea. It would be extremely unlikely for Elite to have beaten Intas to the punch after they paved the way winning lawsuits vs Purdue to nullify some parents. Being along the first is still huge.
Look at the date. That was from 3 weeks ago. That’s old news dude.
I have you blocked and just happened to see this. Yes, you are correct in reading a basic P&L. This is why you don’t exclude R&D. You overstate earnings otherwise and everything from earnings to multiples are off. Don’t argue with a financial consultant. You can go back to your government cube now.
And Concerta on deck? Would be nice to see how pipeline is getting replenished with larger drugs.
Looking forward to hearing more on Prasco expectations. I expect that to be a solid stream of rev.
Can we get to 0.15 and get rid of jammy today? Glory is on the horizon.